JPRN-UMIN000038357已完成未知
Additional S1 chemotherapy for patients underwent non curative ESD for gastric cancer:exploratory clinical trial - Additional S1 chemotherapy for patients underwent non curative ESD for gastric cancer (SPEC trial)
适应症
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 入组人数
- 9
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 85years-old（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •1)Synchronous double/multiple cancer or metachronous double/multiple cancer with progression free period of 5 years or shoter, except mucosal cancer treated by endoscopic resection 2) previous gastrectomy 3) Infection requiring systemic treatment 4) Women expecting pregnancy, in pregnancy, in possible pregnancy or in breast feeding 5) Male expecting partner's pregnancy 6) Severe mental disease 7) Under treatment by flucytosine, phenytoin, or warfarin potassium 8) Uncontrolled diabetes mellitus 9) severe lung disease (Interstitial pneumonia, severe emphysema and so on) 10) unstable angina or myocardial infarction within 6 months
研究者
相似试验
招募中
2 期
RR001, a cell-based gene therapy administered in combination with chemotherapy for the treatment of patients with locally advanced pancreatic cancer. Phase I /IIa clinical trial (open label and non-randomized) to test the effects (safety & efficacy) of increasing doses of RR001.2024-516019-26-00Eir Biotherapies S.r.l.18
已完成
不适用
"Adjuvant Chemotherapy Trial of S-1 for breast cancer with ER-positive and HER2-negative" Pharmacodynamics, Pharmacokinetics and Pharmacogenomics studyFemale patient with invasive breast cancerJPRN-UMIN000006194Graduate School of Medicine Kyoto University1,400
进行中（未招募）
不适用
Chemotherapy of first line reinforced for cancers of the colonist and the rectum with hepatic and/or pulmonary metastases potentially résécables: Strong association FOLFIRI and ERBITUX - ERBIFORTcancers of the colonist and the rectumEUCTR2007-000357-54-FRniversityHospitalGrenoble
已完成
2 期
ESOX trialadenocarcinoma of the esophagogastric junctionJPRN-jRCTs051180192Watanabe Masayuki50
招募中
2 期
A phase II study of systemic chemotherapy with S-1 plus oxaliplatin followed by surgery in T3/T4a and/or lymph node-positive advanced adenocarcinoma of the esophagogastric junctioJPRN-UMIN000020815Cancer Institute Hospital, Gastroenterological Chemotherapy Department50